Premier Biomedical Inc · OTC:BIEI
Premier Biomedical — Investor Presentation (September 2012)
12 slides from Premier Biomedical's investor presentation, September 2012
Slide 1: Business Presentation
Business Presentation September 2012 ©2012 confidential and proprietary. All rights reserved
Slide 2: Today
today • why PBI • what is The Felder DoctrineTM • PBI business model • sequential dialysis and Feldetrex • medical team • timeline ©2012 confidential and proprietary. All rights reserved
Slide 3: To date there is still no cure!
According to World Health Organization (WHO) chronic diseases, such as heart disease, stroke, cancer, chronic respiratory diseases and diabetes, are by far the leading cause of mortality in the world, representing 63% of all deaths out of the 36 million people who died in 2008. To date there is stil
Slide 4: Mitchell S. Felder, M.D. and Dr. James Watson
In order to grow, thrive and metastasize, cancer tissue is dependent upon the presence of certain molecular compounds: cytokines, antigenic proteins, tumorigenesis proteins, signaling proteins, etc. If these are physically removed the cancer can not thrive or metastasize. Mitchell S. Felder, M.D. Al
Slide 5: The Felder Doctrine
The Felder Doctrine TM Physical removal of the pathophysiologic basis of the disease. ©2012 confidential and proprietary. All rights reserved
Slide 6: The PBI Business Model
The PBI Business model PBI 1. Use the tripod approach UTEP * DOD ** 2. Coordinate our IP with the lab services of a large research based university (UTEP’s $45 million lab) 3. And then add the remarkable services of the Department of Defense (DOD) with their large, unequalled power of animal model c
Slide 7: Sequential dialysis
Sequential dialysis • Our proprietary Sequential-Dialysis Technique is a methodology for the removal of those molecules which are harmful and responsible for causing diseases. – Extracorporeal (outside the body)process to prevent the myriad of severe side effects which are normally encountered. – Th
Slide 8: Feldetrex
Feldetrex™ • Feldetrex™: A proprietary combination of generic medications which is believed to reduce the symptomology of Multiple Sclerosis, Fibromyalgia, and Traumatic Brain Injury. – The dosages, combinations, and ingredients of Feldetrex™ allow it to be efficacious yet have lower side effects. –
Slide 9: Competition / Marketing and Sales
Competition Press Releases will be issued at least once/month. ---NO COMPETITION--- Articles to be authored in daily and Pills, chemotherapy, surgery, etc are monthly periodicals, medical journals. ineffective products/processes, which Participate in symposiums, seminars, have demonstrate little or
Slide 10: Goals and Objectives for Cancer Treatment
Goals and Objectives for Cancer Treatment Kill cancer cells via protein reduction through the Insert utilization of Sequential own your Dialysis and The Felder picture DoctrineTM Goals and Objectives for Alzheimer’s Disease and Use Sequential Dialysis to Traumatic Brain Injury remove unwanted protei
Slide 11: PBI Timeline
PBI Timeline May 2012 – PBI and UTEP sign July 2012 – Collaborative Agreement: • PBI and UTEP sign Scope of December 2010 - PBI incorporated in Nevada Aphaeresis Selective March 2012 – Work Agreement. Dr. Mitchell Felder Depletion of Small Reactive meets with Dr. Robert Molecules and Pathogens that
Slide 12: Contact Information
Contact Information: Richard T. Najarian Chief Investment Officer (248) 709-9878 Safe Harbor Notice Certain statements contained herein are "forward-looking statements" (as defined in the Private Securities Litigation Reform Act of 1995). Premier Biomedical, Inc. cautions that statements made in thi
Premier Biomedical — Investor Presentation (September 2012) on 6ix